Aptilon Corporation Makes a Clarification with Respect to an Item to be Considered at its Annual and Special Shareholders’ Meeting

Montreal, Quebec, June 15, 2007 - Aptilon Corporation (“Aptilon” or the “Corporation”) (TSX-V: APZ), wishes to make the following clarification with respect to the amendment to the existing stock option plan (the “Plan”) to be approved at the shareholders’ meeting to be held on June 28, 2007 (the “Meeting”). In order to comply with the Exchange’s policies and contrary to what the text of the proxy circular pertaining to the Meeting (the “Circular”) indicates, the maximum number of common shares that may be issued pursuant to the Plan will be limited to a fixed number of common shares corresponding to 15% of the number of common shares outstanding at the time of the Circular rather than on a rolling number of common shares. Consequently, the number of shares reserved for issuance under the Plan will be 20,902,711 representing 15 % of the 140,055,410 common shares outstanding as of the date of the Circular less 105,600 (the 105,600 figure being the number of options granted to former directors of the Corporation still outstanding).

About Aptilon Corporation
Aptilon enables pharmaceutical, biotech, and medical device companies to effectively reach and interact with physicians via the Internet through its innovative live video detailing (with company reps), e-detailing, e-sampling, peer selling, and other educational content programs. Leading healthcare companies have adopted Aptilon’s “Sales Force of the Future” model, driving tens of thousands of high-quality rep-physician interactions averaging 8 to 10 minutes in length. Aptilon provides the necessary infrastructure for sales representatives to build physician awareness, understanding, and preference during all stages of a product life cycle, from pre-launch education through to end-stage support. For more information, visit www.aptilon.com.

###